Treats definite or suspected acute myocardial infarction. ANDA 91045, held by Fresenius Kabi USA. Metoprolol Tartrate.
As of Nov 22, 2026, ANDA 91045 (Metoprolol Tartrate), held by Fresenius Kabi USA, was first approved by FDA on Oct 25, 2010, with 3 approved supplements and 0 published complete response letters.
INDICATIONS & USAGE Myocardial Infarction Metoprolol tartrate injection is indicated in the treatment of hemodynamically stable patients with definite or suspected acute myocardial infarction to reduce cardiovascular mortality. Treatment with intravenous metoprolol tartrate injection can be initiated as soon as the patient’s clinical condition allows (see DOSAGE & ADMINISTRATION, CONTRAINDICATIONS, and WARNINGS ). Alternatively, treatment can begin within 3 to 10 days of the acute event (see DOSAGE & ADMINISTRATION ).
| Date | Submission | Status | Documents |
|---|---|---|---|
| Oct 25, 2010 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Metoprolol Tartrate1MG/ML · injectable;injection | Metoprolol Tartrate | Rx |
| Nov 13, 2024 | Supplement 4Labeling · Standard review | Approved | None posted |
| Sep 15, 2021 | Supplement 3Labeling · Standard review | Approved | None posted |
| Aug 13, 2015 | Supplement 1Labeling · Standard review | Approved | None posted |
| Oct 25, 2010 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters